PMX-30063: Phase II started

Polymedix began a single-blinded, Canadian Phase II trial in up to 200 patients to compare 3 doses of once-daily IV PMX-30063 for 5 days followed by placebo for 2 days vs. once-daily Cubicin daptomyc...